AU1290001A - Antibodies - Google Patents

Antibodies

Info

Publication number
AU1290001A
AU1290001A AU12900/01A AU1290001A AU1290001A AU 1290001 A AU1290001 A AU 1290001A AU 12900/01 A AU12900/01 A AU 12900/01A AU 1290001 A AU1290001 A AU 1290001A AU 1290001 A AU1290001 A AU 1290001A
Authority
AU
Australia
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12900/01A
Other languages
English (en)
Inventor
Christopher Robert Bebbington
Miles William Carroll
Fiona Margaret Ellard
Alan Kingsman
Susan Mary Kingsman
Kevin Alan Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1999/003859 external-priority patent/WO2000029428A2/en
Priority claimed from GB0003527A external-priority patent/GB0003527D0/en
Priority claimed from GB0005071A external-priority patent/GB0005071D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of AU1290001A publication Critical patent/AU1290001A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU12900/01A 1999-11-18 2000-11-13 Antibodies Abandoned AU1290001A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
WOGB99/03859 1999-11-18
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy
GB0003527 2000-02-15
GB0003527A GB0003527D0 (en) 2000-02-15 2000-02-15 Antibodies
GB0005071 2000-03-02
GB0005071A GB0005071D0 (en) 2000-03-02 2000-03-02 Antibodies
PCT/GB2000/004317 WO2001036486A2 (en) 1999-11-18 2000-11-13 Scfv antibodies against disease associated molecules

Publications (1)

Publication Number Publication Date
AU1290001A true AU1290001A (en) 2001-05-30

Family

ID=27255534

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12900/01A Abandoned AU1290001A (en) 1999-11-18 2000-11-13 Antibodies

Country Status (7)

Country Link
US (4) US7074909B2 (enExample)
EP (1) EP1242456B1 (enExample)
JP (1) JP2003515323A (enExample)
CN (1) CN1423660A (enExample)
AU (1) AU1290001A (enExample)
CA (1) CA2391925A1 (enExample)
WO (1) WO2001036486A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2292760A1 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
WO2001036486A2 (en) 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
WO2002038612A2 (en) * 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
KR20050048615A (ko) * 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2006017325A2 (en) * 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins the same
GT200500255A (es) * 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
EP1870458B1 (en) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2006132352A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
RU2009111138A (ru) 2006-10-12 2010-11-20 Вайет (Us) Способы и композиции с уменьшенной опалесценцией
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
KR100949791B1 (ko) * 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
WO2010007365A1 (en) * 2008-07-15 2010-01-21 Oxford Biomedica (Uk) Ltd Immunotherapeutic method
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
AU2012311492A1 (en) * 2011-09-23 2014-03-06 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5T4 and CD3
ES2724232T3 (es) 2012-01-24 2019-09-09 Pfizer Procedimientos de detección de células tumorales circulantes positivas para 5T4 y procedimientos de diagnóstico de cáncer positivo para 5T4 en un sujeto mamífero
EP3010939A2 (en) 2013-06-17 2016-04-27 Asana BioSciences, LLC 5t4-targeted immunofusion molecule and methods
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
WO2015054669A1 (en) * 2013-10-11 2015-04-16 Asana Biosciences, Llc Protein-polymer-drug conjugates
EA032231B1 (ru) 2013-10-11 2019-04-30 Мерсана Терапьютикс, Инк. Конъюгаты белок-полимер-лекарственное средство
JPWO2015133484A1 (ja) * 2014-03-04 2017-04-06 国立大学法人徳島大学 腎臓疾患に関するマーカー及びその利用
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
CN106749656B (zh) * 2016-11-11 2018-04-13 郑州师范学院 一种抗小鼠RCN3蛋白单克隆ScFv抗体及其淘选方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018167486A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
EP3704151A4 (en) 2017-11-01 2021-07-28 NantBio, Inc. EMT PATH BLOCKING IINTERLEUKIN 8 AND CONTROLLING CARCINOUS STEM CELLS
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP2021506883A (ja) 2017-12-21 2021-02-22 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピン抗体結合体
AU2019233523A1 (en) 2018-03-12 2020-10-01 Genmab A/S Antibodies
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
WO2024197151A2 (en) 2023-03-22 2024-09-26 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481051A (en) * 1969-02-06 1969-12-02 Paramount Packaging Corp Heating apparatus
US4009778A (en) * 1975-11-04 1977-03-01 The Kartridg Pak Co. Dual compartment package and method for making same
US4267768A (en) * 1976-09-20 1981-05-19 David M. Cieslak Process for fabricating a reclosable bag
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
DE68923027D1 (de) * 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5060146A (en) 1988-04-08 1991-10-22 International Business Machines Corporation Multilingual indexing system for alphabetical lysorting by comparing character weights and ascii codes
CA2016897A1 (en) 1989-05-17 1990-11-17 John W. Wills Retrovirus-mediated secretion of recombinant products
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5582826A (en) * 1993-04-21 1996-12-10 Ajinomoto Co., Inc. Monoclonal antibodies which bind the gamma chain of human interleukin-2 receptor
EP0700444B1 (en) * 1993-05-12 2003-04-02 XOMA Corporation Immunotoxins comprising gelonin and an antibody
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
DK0706799T3 (da) 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
WO1996030504A1 (en) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Modified viral envelope polypeptide
FR2732348B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US5637462A (en) * 1995-04-19 1997-06-10 Incyte Pharmaceuticals, Inc. Cathepsin C homolog
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
ES2252744T3 (es) * 1995-06-06 2006-05-16 Human Genome Sciences, Inc. Gen y proteina especificos del colon.
DE19531346A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
AU7719596A (en) 1995-11-07 1997-05-29 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
JP4175678B2 (ja) * 1996-06-07 2008-11-05 武田薬品工業株式会社 新規ペプチド、その製造法および用途
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
CA2292760A1 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Vector
WO2001036486A2 (en) 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
WO2000029428A2 (en) * 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
JPH1156368A (ja) * 1997-08-27 1999-03-02 Nippon Seibutsu Kagaku Kenkyusho 猫トロンボポエチンの活性を有する因子
AU763020B2 (en) * 1998-03-06 2003-07-10 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies

Also Published As

Publication number Publication date
WO2001036486A2 (en) 2001-05-25
US20100040539A1 (en) 2010-02-18
US20070259400A1 (en) 2007-11-08
JP2003515323A (ja) 2003-05-07
US20110052577A1 (en) 2011-03-03
EP1242456B1 (en) 2008-10-15
CA2391925A1 (en) 2001-05-25
WO2001036486A3 (en) 2002-05-10
EP1242456A2 (en) 2002-09-25
US20060014222A1 (en) 2006-01-19
US7514546B2 (en) 2009-04-07
CN1423660A (zh) 2003-06-11
US7074909B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
AU1290001A (en) Antibodies
AU4935000A (en) Antibodies
AU1173201A (en) Skin-gripper
AU2678800A (en) Modified calycins
AU6045900A (en) Interaction-activated proteins
AU5967600A (en) Candystraw
AU7514700A (en) Cyanopiperidines
AU4115400A (en) Short-circuiter
AU6440900A (en) Homogentisate-dioxygenase
AU2023701A (en) Sketcher
AU2804600A (en) Arylaminoalkylamides
AU2452301A (en) Protein methylarginine-specific antibodies
AU4916900A (en) Benzofuranylsulfonates
AU3191100A (en) Ligand-bonded complex
AU4561600A (en) Benzofuranylaminoalcohols
AU1901801A (en) Glucofuranoses
AU7513400A (en) Hydantoin-racemase
AU4435300A (en) Hula-hoop
AU1915601A (en) Periotome
AU2582200A (en) Windturbine
AU7788600A (en) Colon-tumour-associated antigens
AUPP932199A0 (en) Anti-p53 antibodies
AU5416100A (en) Retinoscopes
AU2197301A (en) Microlamp
AU2001295042A1 (en) Anti-stilbene antibodies

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase